Title: Daedeok-net– Goodbye to big LG, new start as a venture

Publication:  Daedeok-net/ Jeong Sun Moon

Date: 10 June 2011

Summary

• LegoChem Bioscience (CEO Yong Zu Kim) was founded by major researchers who developed the Korea's first global medicine "FACTIVE" in LG Life Science.                                                                 

• Since LG Life Science has been a leading drug development company, LegoChem employees have considerable experience in the area.

• Gathering of drug developing leaders caught the market's attention even before its foundation. Investors' estimated corporate value over $100 million.

• LegoChem aims to become a representative company of drug development industry in next 5~10 years. The company has another goal to become an IPO of NASDAQ stock market to compete in global market. In order to achieve those goals, LegoChem is cooperating with global companies, and government research institutes, as well as other venture companies.

   

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).